JP2006515744A5 - - Google Patents

Download PDF

Info

Publication number
JP2006515744A5
JP2006515744A5 JP2004541534A JP2004541534A JP2006515744A5 JP 2006515744 A5 JP2006515744 A5 JP 2006515744A5 JP 2004541534 A JP2004541534 A JP 2004541534A JP 2004541534 A JP2004541534 A JP 2004541534A JP 2006515744 A5 JP2006515744 A5 JP 2006515744A5
Authority
JP
Japan
Prior art keywords
mhc class
epitope
presenting
key
terminal element
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004541534A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006515744A (ja
Filing date
Publication date
Priority claimed from US10/245,871 external-priority patent/US20030235594A1/en
Priority claimed from US10/253,286 external-priority patent/US7179645B2/en
Application filed filed Critical
Priority claimed from PCT/US2003/028574 external-priority patent/WO2004030616A2/en
Publication of JP2006515744A publication Critical patent/JP2006515744A/ja
Publication of JP2006515744A5 publication Critical patent/JP2006515744A5/ja
Pending legal-status Critical Current

Links

JP2004541534A 2002-09-17 2003-09-12 Ｉｉ−Ｋｅｙ／抗原性エピトープハイブリッドペプチドワクチン Pending JP2006515744A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/245,871 US20030235594A1 (en) 1999-09-14 2002-09-17 Ii-Key/antigenic epitope hybrid peptide vaccines
US10/253,286 US7179645B2 (en) 2002-09-24 2002-09-24 Ii-Key/antigenic epitope hybrid peptide vaccines
PCT/US2003/028574 WO2004030616A2 (en) 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Publications (2)

Publication Number Publication Date
JP2006515744A JP2006515744A (ja) 2006-06-08
JP2006515744A5 true JP2006515744A5 (enExample) 2007-10-18

Family

ID=32072825

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004541534A Pending JP2006515744A (ja) 2002-09-17 2003-09-12 Ｉｉ−Ｋｅｙ／抗原性エピトープハイブリッドペプチドワクチン

Country Status (5)

Country Link
EP (1) EP1556072B1 (enExample)
JP (1) JP2006515744A (enExample)
AU (1) AU2003294220A1 (enExample)
CA (1) CA2499123A1 (enExample)
WO (1) WO2004030616A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
KR20070056042A (ko) * 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US7691396B2 (en) * 2005-06-15 2010-04-06 The Ohio State University Research Foundation Chimeric peptides comprising HER-2 B-cell epitopes and measles virus fusion protein T-cell epitopes
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
JP2012050440A (ja) * 2011-09-16 2012-03-15 Chiba Univ ヒトＴｈ１／Ｔｈ２分化誘導の評価方法
JP6608282B2 (ja) * 2012-10-30 2019-11-20 アラヴァックス ピーティーワイ リミテッド 新規免疫療法用分子およびその使用
RU2689552C2 (ru) * 2013-09-25 2019-05-28 Аравакс Пти Лтд Новая иммунотерапевтическая композиция и ее применения
FI3273986T3 (fi) * 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
KR20220132023A (ko) * 2016-04-19 2022-09-29 임시스 에스에이 신규 면역원성 CD1d 결합 펩티드
CN108129558B (zh) * 2017-12-21 2021-10-12 中国医学科学院北京协和医院 一种桦树花粉主要致敏蛋白Bet v 8的提取和分离纯化方法及应用
US20230000908A1 (en) * 2019-09-11 2023-01-05 Ohio State Innovation Foundation Engineered cells and uses thereof
EP4536244A2 (en) * 2022-06-10 2025-04-16 Ayass Bioscience LLC Food allergen processing and desensitization by aptamers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5194425A (en) 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
DE69020143T2 (de) 1989-02-17 1996-01-25 Chiron Mimotopes Pty Ltd Verfahren zur verwendung und herstellung von peptiden.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
EP0897987B1 (en) 1989-10-24 2001-02-28 Chiron Corporation Secretion of human protein linked to gamma interferon signal peptide
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
EP0558671B1 (en) 1990-11-21 1999-01-27 Iterex Pharmaceuticals Ltd. Partnership Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU671971B2 (en) 1991-11-29 1996-09-19 Chiron Corporation Anti-cancer immunotherapeutic vector constructs
US5679527A (en) 1992-03-25 1997-10-21 Antigen Express, Inc. Modification of polypeptide structure
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5559028A (en) * 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
EP0800545B2 (en) 1995-11-01 2011-03-02 Bracco Research S.A. Targeted magnetically labeled molecular marker systems for the nmr imaging
AU3307497A (en) 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response

Similar Documents

Publication Publication Date Title
ES2279625T3 (es) Compuesto y procedimiento para la prevencion y/o el tratamiento de la alergia.
US10772934B2 (en) Highly active polypeptides and methods of making and using the same
US5580563A (en) Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
Kaumaya et al. Peptide vaccines incorporating a ‘promiscuous’ T‐cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity
JP3802049B2 (ja) Ｈｉｖに対する中和性抗体および細胞障害性ｔリンパ球を誘発する複合合成ペプチド構築物
JP5751741B2 (ja) 免疫原性組成物および使用法
ES2676630T3 (es) Control inmunogénico de tumores y células tumorales
JP2020506690A5 (enExample)
JPH04502760A (ja) エイズの診断，予防および治療に有効な新規ｈｉｖ蛋白質およびペプチド
JP2006020648A5 (enExample)
JP2003529319A (ja) ＨＩＶ−１ｇｐ４１を標的化する広範に中和する抗体を誘発する方法
JP2001502658A (ja) 非樹状中心骨格ペプチド担体
Huang et al. Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine
RU2337922C9 (ru) ИЗОЛИРОВАННЫЕ ПОЛИПЕПТИДЫ НА ОСНОВЕ НЕЙТРАЛИЗУЮЩЕГО ЭПИТОПА БЕЛКА p17 ВИРУСА ВИЧ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ВАКЦИН, А ТАКЖЕ НЕЙТРАЛИЗУЮЩИЕ АНТИ-p17-АНТИТЕЛА, СПЕЦИФИЧЕСКИ РАСПОЗНАЮЩИЕ УКАЗАННЫЙ НЕЙТРАЛИЗУЮЩИЙ ЭПИТОП
CN1054772A (zh) 合成多肽
Curicio‐Vonlanthen et al. Molecular parameters in melittin immunogenicity
JP2002536384A (ja) Ｔヘルパー細胞エピトープ
JPH07506374A (ja) う蝕予防用合成ペプチドワクチン
US20030152581A1 (en) Compound and method for the prevention and/or the treatment of allergy
Dakappagari et al. Intracellular delivery of a novel multiepitope peptide vaccine by an amphipathic peptide carrier enhances cytotoxic T‐cell responses in HLA‐A* 201 mice
Ferru et al. Analysis of the immune response elicited by a multiple antigen peptide (MAP) composed of two distinct protective antigens derived from the parasite Schistosoma mansoni
ES2322253T3 (es) Utilizacion de mezclas de lipopeptidos para la fabricacion de vacunas.
JPH07505878A (ja) Ｈｉｖエンベロープ糖タンパク質から誘導された合成ポリペプチド
CN100387616C (zh) 获得可增强特异交叉反应性的抗原结构的方法
JPS58222031A (ja) 合成ワクチン